G1 Therapeutics’ Phase 3 trial of trilaciclib for metastatic triple negative breast cancer continues as planned
In a significant update for the oncology community, G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage company specializing in cancer treatment, announced the continuation of its ... Read More
FDA approves G1 Therapeutics’ Cosela for reducing chemotherapy-induced bone marrow suppression
G1 Therapeutics has achieved a significant milestone with the recent U.S. Food and Drug Administration (FDA) approval of Cosela (trilaciclib), a pioneering treatment designed to ... Read More